Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients

Clinical Microbiology and Infection

Volumn 19, Issue 5, 2013, Pages 474-479

  Gudiol, C ^a,b   Bodro, M ^a,b   Simonetti, A ^a   Tubau, F ^a,c   Gonzalez Barca E ^d   Cisnal, M ^a   Domingo Domenech, E ^d   Jimenez L ^d   Carratala J ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antimicrobial resistance; Bacteraemia; Bloodstream infection; Cancer; Changing epidemiology; Neutropenia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN; POLYPEPTIDE ANTIBIOTIC AGENT; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAEROBE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; FEMALE; FUNGUS; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; SOFT TISSUE INFECTION; URINARY CATHETER;

BACILLI (CLASS); NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS;

EID: 84876334028     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03879.x     Document Type: Article

References (36)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med 1966; 64: 328-340.
2. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. Am J Med 1977; 62: 731-742.
3. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-494.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
5. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004; 39 (suppl 1): S25-S31.
6. Marron A, Carratalà J, González-Barca E, Fernández-Sevilla A, Alcalde F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31: 1126-1130.
7. Cometta A, Zinner S, de Bock R et al. Piperacillin-tazobacteam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for research and treatment of cancer. Antimicrob Agents Chemother 1995; 39: 445-452.
8. Carratalà J, Alcaide F, Fernández-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995; 20: 1169-1173.
9. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-1207.
10. Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149-158.
11. González-Barca E, Fernández-Sevilla A, Carratalà J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-296.
12. Clinical and Laboratory Standards Institute (Formely NCCLS). Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21 Vol 31 No. 1 [ISBN 1-56238-588-7]. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA, 2011.
13. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 1619-29.
14. Murray PR, Baron EJ, Jorgersen JH, Landry ML, Pfaller MA (eds). Manual of clinical microbiology, 9th edn. American Society of Microbiology, Washington, DC, 2007.
15. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; Approved Standard-Eight Edition. CLSI document M07-A8 Vol 29 No 2 [ISBN 1-56238-607-7]. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2009.
16. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility test; approved standard-tenth edition. CLSI document M02-A10 (ISBN 1-56238-688-3). Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2009.
17. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quionolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5-22.
18. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-e93.
19. Carratalà J, Fernández-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-505.
20. Carratalà J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560.
21. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1241.
22. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-687.
23. Asensio A, Alvarez-Espejo T, Fernández-Crehuet J et al. Trends in yearly prevalence of third-generation and fluoroquionolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Euro Surveill 2011; 16: pii:19983.
24. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
25. LeBlanc L, Pépin J, Toulouse K et al. Fluoroquinolones and risk for methicillin-resistant Staphyloccocus aureus, Canada. Emerg Infect Dis 2006; 12: 1398-1405.
26. Pépin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
27. Winston DJ, Dudnik DV, Chapin M, Ho WG, Gale RP, Martin WJ. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 1983; 143: 32-36.
28. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31.
29. Oliveira AL, Souza M, Carvalho-Dias VM et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007; 39: 775-781.
30. Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-1414.
31. Jacobson K, Rolston K, Elting L, LeBlanc M, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 1999; 45: 325-334.
32. Krcméry V Jr, Spanik S, Krupova I et al. Bacteraemia due to multi-resistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Chemother 1998; 10: 320-325.
33. Gudiol C, Tubau F, Calatayud L et al. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66: 657-663.
34. Tumbarello M, Spanu T, Caira M et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009; 64: 320-326.
35. Wisplinghoff H, Cornely OA, Moser S et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 2003; 24: 905-911.
36. Kang CI, Kim SH, Park WB et al. Bloodstream infections caused antibiotic resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760-766.